ProQR Therapeutics NV (NAS:PRQR)

$ 1.89 -0.05 (-2.58%) Market Cap: 154.34 Mil Enterprise Value: 67.80 Mil PE Ratio: 0 PB Ratio: 4.11 GF Score: 37/100

ProQR Therapeutics NV R&D Day Transcript
Mar 29, 2023
ProQR Therapeutics NV Lilly Partnership Expansion and Axiomer Overview Transcript
Dec 22, 2022
ProQR Therapeutics NV Management Call Transcript
Aug 11, 2022
ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call Transcript
Apr 13, 2022
ProQR Therapeutics NV Top-Line Results Phase 2/3 Illuminate Trial - Corporate Call Transcript
Feb 11, 2022
ProQR Therapeutics NV Analyst Event Transcript
Nov 18, 2021
ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
ProQR Therapeutics NV at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021
ProQR Therapeutics NV Axiomer RNA Call Transcript
Sep 09, 2021
ProQR Therapeutics NV Review of Phase 1/2 Stellar Data in Usher/nsRP Hosted By Cantor Fitzgerald Transcript
Mar 25, 2021
ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP Transcript
Mar 24, 2021
ProQR Therapeutics NV at H C Wainwright Global Life Sciences Conference (Virtual) Transcript
Mar 09, 2021
ProQR Therapeutics NV Expert Perspectives Call Transcript
Feb 22, 2021
Apellis Pharmaceuticals Inc, Aerie Pharmaceuticals, Aldeyra Therapeutics, and ProQR Therapeutic at Citi BioPharma Conference (Virtual) - Panel Transcript
Sep 10, 2020
ProQR Therapeutics NV Expert Perspectives Series -- LCA10 and Sepofarsen - Call Transcript
Jul 20, 2020
ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call Transcript
Jun 22, 2020

ProQR Therapeutics NV Management Call Transcript

Aug 11, 2022 / 12:15PM GMT

Release Date Price: $0.815 (-2.96%)

Transcript

Sarah Cue Kiely

ProQR Therapeutics N.V. - VP of IR & Corporate Communications

Thank you, operator, and good day, everyone. We appreciate you joining the call. I'm Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR. Today, we issued a press release announcing that going forward, we will focus exclusively on our RNA-editing platform technology, and will seek to partner our ophthalmology program. This press release can be found on our website at www.proqr.com.

With me today from the management team is Daniel de Boer, our Founder and CEO. Following Daniel's prepared remarks, we will have a Q&A session, which will include Daniel, along with Rene Beukema, our Chief Corporate Development Officer.

In order to include your question on today's call, we request that you use the phone numbers provided via the webcast link. During the call today, we will make forward-looking statements. There are risks and uncertainties associated with an investment in ProQR, which are described in detail in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.